Indegene acquires Medical Marketing Economics for around $10 mn

Healthcare solutions provider Indegene on Monday said it has acquired MME for approximately $10 million to strengthen its pricing, reimbursement and market access capabilities.

Indegene acquires Medical Marketing Economics for around $10 mn
Press Trust of India New Delhi
2 min read Last Updated : Aug 30 2021 | 11:30 PM IST

Healthcare solutions provider Indegene on Monday said it has acquired Medical Marketing Economics, LLC (MME) for approximately USD 10 million (around Rs 73 crore) to strengthen its pricing, reimbursement and market access capabilities.

MME is a global leader in pricing, reimbursement and market access (PRMA) services, Indegene said in a statement.

"Their 40+ strong team will strengthen our emerging Biotech and Medical offerings. They bring proven PRMA capabilities that complement our Co-Commercialization solution," Indegene Cofounder and CEO Manish Gupta said.

Pricing, reimbursement and market access is a strategic area of interest for Indegene. It augments company's reach both with the big pharma companies and emerging biotech companies, and complements its digital first commercialization practice, he added.

"The current size of the market access solutions market is USD 1.7 billion and expected to increase to USD 2.24 billion over the next five years, signalling a great headroom opportunity for us in the US market. Acquiring MME(Medical Marketing Economics, LLC), is a step in this direction. The size of this deal is approximately USD 10 million," Gupta said.

On the development, MME, Global President and CEO, Jack M. Mycka said, "This partnership gives us access to a larger customer base, a global operations infrastructure, and significant opportunities for growth through adjacent services. Alongside Indegene's clinical, medical and commercial solutions, we can further help clients identify, frame, communicate and capture the value of their medical innovations."

Emerging Biotech organisations contribute about 75 per cent of the products in the pipeline and this is only expected to grow, the statement said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Healthcare sectorMarketing

First Published: Aug 30 2021 | 11:30 PM IST

Next Story